To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Lindane, also known as gamma-hexachlorocyclohexane (γ-HCH) and benzene hexachloride (BHC), is an organochlorine insecticide that has been used in agriculture and in pharmaceutical products for the treatment of headlice and scabies.
Lindane is a neurotoxin that interferes with GABA neurotransmitter function by interacting with the GABAA receptor-chloride channel complex at the picrotoxin binding site. It has an oral LD50 of 88 mg/kg in rats and a dermal LD50 of 1000 mg/kg. In humans, lindane primarily affects the nervous system, liver and kidneys, and may be a carcinogen and/or endocrine disruptor.
The World Health Organization classifies lindane as "Moderately Hazardous," and its international trade is restricted and regulated under the Rotterdam Convention on Prior Informed Consent. It is presently banned in more than 50 countries, and is being considered for inclusion in the Stockholm Convention on persistent organic pollutants, which would ban its production and use worldwide.
Additional recommended knowledge
Agricultural vs. Healthcare Applications
Lindane has been used in the U.S. for more than 60 years, both in healthcare and in agriculture. In the 1940s, lindane was registered with the U.S. Department of Agriculture (USDA), and in 1951 it was approved by the U.S. Food and Drug Administration (FDA) for medical use in the treatment of scabies, head lice and pubic lice (crabs). During this time, the vast majority of lindane use―more than 99%―has been for agricultural purposes and much of the safety and environmental concerns have related to this application.  This is not unlike other medications where the active ingredient has other non-healthcare applications. For example, warfarin is used as a rodenticide to poison mice and rats (e.g., Kaput™, D-Con™) but is also formulated for medical use as an oral anticoagulant or "blood thinner" to treat patients with heart attacks, strokes and other clot-related disorders (e.g., Coumadin®).
In 2006, the U.S. Environmental Protection Agency (EPA) called for the voluntary cancellation of all agricultural uses of lindane, limited in recent years to pre-planting seed treatments. (see also Regulatory Status) The FDA, however, continues to support the use of lindane prescription medications, noting that “The risk of occupational/environmental exposure should be assessed separately and independent of the risk related to the therapeutic use of a medication to treat a medical condition where there is direct benefit to the patient.”  (see also Regulatory History) Repeatedly, the FDA has concluded that lindane medications provide public health benefits at an acceptably low level of risk—a factor for all medications.
In 1995, lindane medications were designated second-line and are now reserved for patients who are unable to tolerate or have failed first-line treatments—a growing problem in the U.S. and elsewhere due to increased rates of resistance. The U.S. Centers for Disease Control and Prevention also includes lindane medications in their Sexually Transmitted Disease Treatment Guidelines as viable treatment alternatives for the management of scabies and pubic lice, consistent with the approved prescription labeling for these products. (see also Pharmaceutical Uses) Other countries, like Canada, similarly approve of pharmaceutical applications for lindane but no longer permit its broader use agriculturally. (see also Regulatory Status)
In the U.S., lindane medications are approved for the treatment of scabies, pubic lice (crabs), and head lice. Both medications contain only the gamma-HCH isomer, and are available as prescription-only medications. They are second line treatments, meaning they are prescribed only when first-line therapies have failed, cannot be tolerated or are otherwise contraindicated.
In the U.S., lindane medications are exclusively manufactured and distributed by Morton Grove Pharmaceuticals, Inc. The company’s promotion agreement with Alliant Pharmaceuticals, which commenced in 2005, was terminated May 2007.
The State of California banned the pharmaceutical use of lindane, effective 2002. A recent analysis concluded that a majority of pediatricians had not experienced problems treating lice or scabies since that ban took effect. The study also documented a marked decrease in lindane wastewater contamination and lindane poisoning incidents reported to Poison Control Centers. The authors concluded that "The California experience suggests elimination of pharmaceutical lindane produced environmental benefits, was associated with a reduction in reported unintentional exposures and did not adversely affect head lice and scabies treatment."
The most common side effects associated with topical use of lindane medications are nonserious reactions of the skin, including burning, itching, dryness and rash. Central nervous system stimulation ranging from dizziness to seizures, has also been reported; however, serious effects, like seizures, have almost always resulted from oral ingestion or misuse of medication (e.g., repeated treatments or prolonged applications). Only rarely have seizures and even more rarely fatal reactions been reported when lindane medications were used (presumably) according to directions.
In 2003, the FDA published a safety analysis of adverse events reported in association with the use of lindane medications received through its adverse event monitoring system (“AERS” database) between from 1974 through 2002. The vast majority (85%) of these reports―488 total―were classified as nonserious, while serious events most often resulted from product misuse (80% of serious cases). The most common reports to the FDA were "drug ineffective," followed by convulsions, dermatitis and dizziness. (Note: These events represent the most common reported to the FDA and do not represent the most common events associated with the use of lindane lotion and lindane shampoo overall).
A review of the most serious cases described 15 deaths of which two were confirmed related to lindane misuse including a suicidal ingestion. The direct causes of death for the other cases were attributed to reasons other than lindane. In addition, there were 46 hospitalizations, and seven life-threatening outcomes—five from the same household. Six cases of congenital anomaly were also described–five for infants "possibly" exposed to lindane in utero and one paternal exposure—but no characteristic pattern of effect was noted.
In all age groups, reported adverse events occurred mainly in patients with contraindications to the use of lindane or in those who appeared to have misapplied or orally ingested medication.
Based on these findings, lindane lotion and lindane shampoo were limited to small unit-dose bottles in 2003 by the FDA to mitigate the risk of misuse and further enhance product safety. At the same time, a boxed warning was added to the prescription label to highlight to healthcare providers appropriate use criteria and rare treatment risks. A medication guide, written in plain English, was also developed and is now required by law to be dispensed with every lindane prescription dispensed in the U.S. to better educate patients and caregivers on safe application technique.  When used properly, lindane medications are safe and effective for the diseases they are approved. The most common side effects are nonserious reactions of the skin (e.g., burning, itching, dryness and rash).
The current FDA-approved product labeling emphasizes that lindane medications are contraindicated for use in premature infants and individuals with known uncontrolled seizure disorders and should be used with caution in infants, children, the elderly, and individuals with other skin conditions (e.g., atopic dermatitis, psoriasis) and in those who weigh less than 110 lbs (50 kg) as they may be at risk of serious neurotoxicity. It also notes that careful consideration should be given before prescribing lindane medications to patients with conditions that may increase the risk of seizure, such as HIV infection, history of head trauma or a prior seizure, CNS tumor, the presence of severe hepatic cirrhosis, excessive use of alcohol, abrupt withdrawal from alcohol or sedatives, as well as concomitant use of medications known to lower seizure threshold.
Human Health Effects
While adverse reactions can occur with use of low-dose topical pharmaceutical formulations, serious effects are rare and have most often resulted from the misuse of medication.  (see also Pharmaceutical Uses) Indeed, most of the adverse human health effects reported for lindane have related to agricultural uses and chronic, occupational exposure of seed treatment workers to agricultural-grade lindane. (see also Agricultural vs. Healthcare Applications)
The production and use of lindane in agricultural (both of which have declined significantly in the last 20 years) are the primary causes of environmental contamination, and levels of lindane in the environment have waned in the U.S. from 1986 through 2003, consistent with decreasing agricultural usage patterns.
Lindane is released into the environment during and after agricultural application through volatilization into the atmosphere (estimated at 12-30%), where it has long-range transport potential and can be deposited by rainfall. Lindane in soil can leach to surface and even ground water and can bioaccumulate in the food chain. Most exposure of the general population to lindane results from agricultural uses and the intake of contaminated foods, such as produce, meats and milk. Over time, lindane is broken down in soil, sediment and water into less harmful substances by algae, fungi and bacteria; however, the process is relatively slow and dependent on ambient environmental conditions. The ecological impact of lindane’s environmental persistence continues to be debated.
The US EPA has determined that lindane does not contaminant drinking water in excess of the Agency's level of concern. In 2003, the EPA reported on the results of large-scale water contaminant testing of 16,000 water systems serving 100 million people across the U.S. and found that none contained lindane levels above the maximum contaminant level standard considered safe. Similar findings were noted by U.S. Geologic Survey teams in 1999 and 2000. More specifically, the EPA conducted “down-the-drain” estimates of the amount of lindane reaching public water supplies from the use of lindane medications using data from California water treatment facilities, concluding that lindane levels from pharmaceutical sources were “extremely low” and not of concern.
Larger than the issue of lindane toxicity are concerns related to the non-gamma isomers of HCH, namely alpha-HCH and beta-HCH, which are notably more toxic than lindane. Alpha- and beta-HCH were used agriculturally in the U.S. in the form of technical-grade HCH until 1976 and are also produced as manufacturing by-products but are void of insecticidal properties and have little to no use. In the 1940s and 1950s lindane producers stockpiled these isomers in open heaps, which led to ground and water contamination. The International HCH and Pesticide Forum has since been established to bring together experts to address the clean-up and containment of these sites. Modern manufacturing standards for lindane involve the treatment and conversion of waste isomers to less toxic industrial chemicals, a process known as “cracking.” Today, only a few production plants remain active worldwide to accommodate public health uses of lindane and declining agricultural needs. Lindane has not been manufactured in the U.S. since the mid-1970s but continues to be imported and formulated for restricted use.
Lindane is registered for use in 50 countries, with restricted-use status in 33 of these countries. The latter includes the U.S. and Canada, which support public health uses of pharmaceutical lindane but no longer allow agricultural applications. It is banned in 52 countries and the state of California, and is under review for addition to the Stockholm Convention On Persistent Organic Pollutants.The US FDA continues to maintain that lindane medications have necessary health benefits that outweigh potential risks and should remain available for patients with head lice, scabies and pubic lice (crabs) who have few treatment alternatives. These infectious diseases, two of which are sexually transmitted, affect tens of millions of Americans and hundreds of millions of people worldwide every year. In the U.S., petitions to ban the use of pharmaceutical lindane have been rejected by the FDA and determined to be without merit by experts working with this regulatory agency. Worldwide, effective treatment options for the control of scabies and lice are relatively limited.
Canada’s Pest Management Regulatory Agency phased out of all agricultural uses of lindane between 2000 and 2005 due to concerns of chronic occupational exposure and risks to workers during seed treatment and planting. However, lindane medications remain available in Canada for public health purposes as non-prescription therapies. In 2002, the EPA concluded that lindane agricultural products were eligible for re-registration given industry compliance with certain data and labeling requirements to mitigate occupational risks to workers. However, in 2006, the Agency published an addendum to its initial decision and called for the voluntary cancellation of all agricultural uses by registered manufacturers (effective July 2007), citing a significant change in the costs and benefits of agricultural uses due to the recent introduction of seed-treatment alternatives to lindane. The EPA has approved the use of lindane stockpiles through 2009. Mexico has committed to a structured, voluntary phase out of lindane through the North American Regional Action Plan (NARAP) but currently authorizes agricultural, veterinary and healthcare uses. There is a bill in the New York State Assembly and Senate to ban its use in head lice products and limit its use on scabies, which had not passed as of September 2007.
Morton Grove Lawsuit
In the face of negative publicity concerning lindane pharmaceutical products, the U.S. manufacturer, Morton Grove Pharmaceuticals, filed a legal complaint on February 6, 2007 in the U.S. District Court in Chicago, Illinois against the National Pediculosis Association, the Ecology Center, Inc., and two physicians for statements made and disseminated to healthcare providers and consumers using the internet and through a series of printed literature . As noted by the U.S. District Court, the case pleads that “[d]efendants swap agricultural and pharmaceutical research selectively quoting and/or misstating findings from studies relating to the agricultural use of lindane, and widely disseminate false, misleading, and defamatory statements about the safety profile and effectiveness of lindane.” On June 18, 2007, Judge Elaine Bucklo issued a written decision denying defendant’s motion to dismiss and further held that Morton Grove had properly pled a case suitable for trial on the following counts: defamation, false advertising under the Federal Lanham Act, trade disparagement and violation of the Illinois Uniform Deceptive Trade Practice Act. The company seeks damages and injunctive relief against all of the defendants. 
In response to Morton Grove's complaint, the Ecology Center defendants moved to dismiss the case based on an alleged lack of personal jurisdiction. However, Morton Grove presented new facts supporting its case for jurisdiction in Illinois and the Court held that Morton Grove's "Second Amended Complaint would provide specific jurisdiction over the Center and Weil." (June 8, 2007 order)
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lindane". A list of authors is available in Wikipedia.|